| Literature DB >> 21849452 |
Georgia D Tomaras1, James M Binley, Elin S Gray, Emma T Crooks, Keiko Osawa, Penny L Moore, Nancy Tumba, Tommy Tong, Xiaoying Shen, Nicole L Yates, Julie Decker, Constantinos Kurt Wibmer, Feng Gao, S Munir Alam, Philippa Easterbrook, Salim Abdool Karim, Gift Kamanga, John A Crump, Myron Cohen, George M Shaw, John R Mascola, Barton F Haynes, David C Montefiori, Lynn Morris.
Abstract
A small proportion of HIV-infected individuals generate a neutralizing antibody (NAb) response of exceptional magnitude and breadth. A detailed analysis of the critical epitopes targeted by broadly neutralizing antibodies should help to define optimal targets for vaccine design. HIV-1-infected subjects with potent cross-reactive serum neutralizing antibodies were identified by assaying sera from 308 subjects against a multiclade panel of 12 "tier 2" viruses (4 each of subtypes A, B, and C). Various neutralizing epitope specificities were determined for the top 9 neutralizers, including clade A-, clade B-, clade C-, and clade A/C-infected donors, by using a comprehensive set of assays. In some subjects, neutralization breadth was mediated by two or more antibody specificities. Although antibodies to the gp41 membrane-proximal external region (MPER) were identified in some subjects, the subjects with the greatest neutralization breadth targeted gp120 epitopes, including the CD4 binding site, a glycan-containing quaternary epitope formed by the V2 and V3 loops, or an outer domain epitope containing a glycan at residue N332. The broadly reactive HIV-1 neutralization observed in some subjects is mediated by antibodies targeting several conserved regions on the HIV-1 envelope glycoprotein.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21849452 PMCID: PMC3194956 DOI: 10.1128/JVI.05363-11
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 5.103